NeuroBo Pharmaceuticals’ DA-1726 shows promising results in pre-clinical obesity treatment studies
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology firm, announced promising pre-clinical data for DA-1726, a novel oxyntomodulin (OXM) analog functioning as a dual agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The data was presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida. The pre-clinical studies showcased DA-1726’s superiority […]